Maze Therapeutics Inc.

11/05/2025 | Press release | Distributed by Public on 11/05/2025 15:15

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Third Rock Ventures IV, L.P.
2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [MAZE]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O THIRD ROCK VENTURES, LLC, 201 BROOKLINE AVE, SUITE 1401
3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025
(Street)
BOSTON, MA 02215
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/04/2025 J(1) 1,600,000 D (1) 4,473,958 D(2)(4)
Common Stock 950,800 I See Footnotes(3)(4)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Third Rock Ventures IV, L.P.
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
BOSTON, MA 02215
X
Third Rock Ventures GP IV, L.P.
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
BOSTON, MA 02215
X
TRV GP IV, LLC
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
BOSTON, MA 02215
X
Third Rock Ventures V, L.P.
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
BOSTON, MA 02215
X
Third Rock Ventures GP V, LP
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
BOSTON, MA 02215
X
TRV GP V, LLC
C/O THIRD ROCK VENTURES, LLC
201 BROOKLINE AVE, SUITE 1401
BOSTON, MA 02215
X

Signatures

/s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P., general partner of Third Rock Ventures IV, L.P. 11/05/2025
**Signature of Reporting Person Date
/s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P. 11/05/2025
**Signature of Reporting Person Date
/s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC 11/05/2025
**Signature of Reporting Person Date
/s/ Kevin Gillis, Chief Operating Officer of TRV GP V, LLC, general partner of Third Rock Ventures GP V, L.P., general partner of Third Rock Ventures V, L.P. 11/05/2025
**Signature of Reporting Person Date
/s/ Kevin Gillis, Chief Operating Officer of TRV GP V, LLC, general partner of Third Rock Ventures GP V, L.P. 11/05/2025
**Signature of Reporting Person Date
/s/ Kevin Gillis, Chief Operating Officer of TRV GP V, LLC 11/05/2025
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) On November 4, 2025, Third Rock Ventures IV, L.P. ("TRV IV ") distributed, for no consideration, 1,600,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP IV, L.P. ("TRV GP IV "), the general partner of TRV IV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP IV distributed, for no consideration, the Shares it received in the distribution by TRV IV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
(2) The shares are held directly by TRV IV. The general partner of TRV IV is TRV GP IV. The general partner of TRV GP IV is TRV GP IV LLC. Each of TRV GP IV, and TRV GP IV LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
(3) The shares are held directly by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V, and TRV GP V LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
(4) Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Maze Therapeutics Inc. published this content on November 05, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on November 05, 2025 at 21:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]